mycobacteria

Kanamycin sulfate (Kanamycin monosulfate) is an aminoglycoside antibiotic that interferes with protein synthesis by binding to the 70S ribosomal subunit of bacteria. Kanamycin sulfate exhibits antimicrobial activity against both Gram-positive and Gram-negative bacteria, as well as mycoplasmas.

Ostruthin (Ostruthine) is a natural coumarin with antimicrobial activity that can effectively inhibit the growth of a wide range of mycobacteria with a minimum inhibitory concentration of MIC= 3.4-107.4 μM.

Senfolomycin B exhibits activity against Gram-positive bacteria and mycobacteria, as well as effectiveness against penicillin-resistant, streptomycin-resistant, neomycin-resistant, and macrolide-antibiotic-resistant Staphylococcus aureus. Additionally, Senfolomycin A demonstrates weaker activity against Gram-negative bacteria.

Roseorubicin B exhibits activity against Gram-positive bacteria and mycobacteria. It also demonstrates inhibitory effects on leukemia cells L1210, with an IC50 of 0.06 μg/mL.

Napyradiomycin A2 is an antibiotic that exhibits activity against Gram-positive bacteria and mycobacteria.

Liposidomycin C exhibits antibacterial properties, though its activity is relatively weak. It shows significant inhibitory effects on mycobacteria with a minimum inhibitory concentration (MIC) of 0.16 μg/mL. Additionally, Liposidomycin C inhibits glycopeptide biosynthesis, effectively suppressing Escherichia coli glycopeptide biosynthesis with an IC50 of 0.03 μg/mL.

Nemotinic acid exhibits activity against Gram-positive bacteria, mycobacteria, and fungi, while also displaying weaker activity against Gram-negative bacteria.

Liposidomycin B exhibits antibacterial properties, although its activity is relatively weak. It shows a significant inhibitory effect on mycobacteria with an MIC of 0.16 μg/mL. Additionally, Liposidomycin B hinders glycopeptide biosynthesis, effectively inhibiting glycopeptide biosynthesis in Escherichia coli with an IC50 of 0.03 μg/mL.

Mannosyl glucosaminide is an aminoglycoside antibiotic with activity against bacteria, mycobacteria, and Saccharomyces cerevisiae (brewer's yeast).

Paromomycin II is an aminoglycoside antibiotic that exhibits activity against both Gram-positive and Gram-negative bacteria, mycobacteria, and protozoa. It is particularly effective in treating amoebic dysentery and certain bacterial dysentery cases.

Granaticin A inhibits the initial stages of RNA biosynthesis and exhibits activity against Gram-positive bacteria, mycobacteria (weak), and Trichomonas vaginalis, as well as tumor cells.

Hedamycin is an anthraquinone antibiotic exhibiting activity against Gram-positive bacteria, Gram-negative bacteria, mycobacteria, and yeasts (MIC of 0.031-3.2 μg/mL). It also inhibits rat duodenal adenocarcinoma, Walker 256 tumors in rats, HeLa cells, and the lysogenic Escherichia coli W1709 (λ) phage.

Mycoplanecin A is a cyclic peptide antibiotic with potent activity against mycobacteria, xanthomonads, and Staphylococcus aureus. Additionally, Mycoplanecin A exhibits moderate antibacterial effects on Xanthomonas oryzae. It also demonstrates antimicrobial activity against certain strains of actinobacteria.

Phleomycin E is a peptide-based antibiotic that is effective against Gram-positive and Gram-negative bacteria as well as mycobacteria. It extends the survival time of mice with transplanted Ehrlich ascites carcinoma and shows inhibitory effects on murine pulmonary solid tumors, with an IC50 of 0.31 μg/mL.

Cycloheptamycin exhibits activity against Gram-positive bacteria and mycobacteria.

Sakyomicin C is a benzoquinone antibiotic. It exhibits activity against Gram-positive bacteria and mycobacteria.

Carriomycin is an antibiotic isolated from Streptomyces hygroscopicus. It is effective against Gram-positive bacteria, mycobacteria, yeast, and fungi, and also serves as a potent anticoccidial agent.

Saframycin E exhibits activity against Gram-positive bacteria and shows weaker activity against mycobacteria.

Roseorubicin A exhibits activity against Gram-positive bacteria and mycobacteria, and it also inhibits leukemia cells L1210, with an IC50 of 0.04 μg/mL.

Oxypyrrolnitrin is a nitrogen-containing heterocyclic antibiotic effective against Gram-positive and Gram-negative bacteria, mycobacteria, and fungi.

Napyradiomycin C2 is an antibiotic with activity against Gram-positive bacteria and mycobacteria.

Saframycin A exhibits antibacterial activity against Gram-positive bacteria and shows weaker effects on Gram-negative bacteria and mycobacteria. Additionally, it inhibits mouse lymphocyte L-1210 cells, with an ID50 of 0.0056 μM.

Etamycin A is an ester peptide antibiotic, primarily exhibiting resistance to Gram-positive bacteria and mycobacteria.

Granaticin B inhibits the initial phase of RNA biosynthesis and exhibits activity against Gram-positive bacteria, mycobacteria (weak), and Trichomonas vaginalis, along with the ability to suppress tumor cells.